Patent US5208219A successfully refreshed from Google Patents.
← Back to Patent Explorer
US5208219A Expired / Lapsed US ⏱️ 0.0 years remaining

Method for inducing bone growth

Assignee: Celtrix Pharmaceuticals Inc
•
Filing: 1991-02-14
•
Granted: 1993-05-04
•
Expires: 2011-02-14
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Activin is administered systemically and locally to induce the growth of mature bone. Activin enhances the level of bone formation and the quality of the bone formed when administered locally with BMP or bone marrow. Administration of activin by subcutaneous route promotes systemic increase in the bone mass.

Inventors

  • 👤 Yasushi Ogawa
  • 👤 David K. Schmidt
  • 👤 Rosa Armstrong
  • 👤 Ranga Nathan
  • 👤 Andrea Y. Thompson
  • 👤 Saeid M. Seyedin

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 23:06
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/575; A; A61; A61K; A61K35/00; A61K35/12; A61K35/28; A61K38/00; A61K38/16; A61K38/17; A61K38/18; A61K38/1841; A61K38/1875; A61L; A61L27/00; A61L27/14; A61L27/22; A61L27/227; A61L27/40; A61L27/44; A61L27/46; A61L27/50; A61L27/54; A61L2300/00; A61L2300/20; A61L2300/252; A61L2300/40; A61L2300/412; A61L2300/414; A61L2300/45

Claims Analysis

Total Claims: 32
Claim 1
Independent Claim 32 words
A method for inducing deposition and maturation of bone in a subject in need thereof, which comprises administering an osteogenically effective amount of activin in a pharmaceutically acceptable excipient to said subject.
Claim 2
Independent Claim 32 words
A method for inducing deposition and maturation of bone in a subject in need thereof, which comprises administering an osteogenically effective amount of activin in a pharmaceutically acceptable excipient to said subject.
Claim 3
Dependent Claim 19 words
The method of claim 1, wherein the activin in a pharmaceutically acceptable excipient is administered systemically to the subject.
Claim 4
Dependent Claim 17 words
The method of claim 1, wherein the activin is administered once per day for about 1-14 days.
Claim 5
Dependent Claim 10 words
The method of claim 1, wherein said subject has osteoporosis.
Claim 6
Dependent Claim 18 words
The method of claim 1, wherein the pharmaceutically acceptable excipient comprises a mixture of collagen and calcium phosphate.
Claim 7
Dependent Claim 17 words
The method of claim 1, which further comprises administering an effective amount of TGF-β to the subject.
Claim 8
Dependent Claim 14 words
The method of claim 6, wherein said activin and the TGF-β are administered simultaneously.
Claim 9
Dependent Claim 14 words
The method of claim 6, wherein said activin and said TGF-β are administered sequentially.
Claim 10
Dependent Claim 18 words
The method of claim 1, which further comprises administering an effective amount of a BMP to the subject.
Claim 11
Dependent Claim 24 words
The method of claim 9, wherein said activin and said BMPs are administered in a ratio of about 1:0.01 to about 1:100 by weight.
Claim 12
Dependent Claim 24 words
The method of claim 9, wherein said activin and said BMPs are administered in a ratio of about 1:0.1 to about 1:1 by weight.
Claim 13
Dependent Claim 16 words
The method of claim 9, wherein said activin and said BMP administered systemically to the subject.
Claim 14
Dependent Claim 20 words
The method of claim 9, wherein said activin and said BMP are administered once per day for about 1-14 days.
Claim 15
Dependent Claim 10 words
The method of claim 9, wherein said subject has osteoporosis.
Claim 16
Dependent Claim 14 words
The method of claim 9, wherein said activin and said BMP are administered simultaneously.
Claim 17
Dependent Claim 14 words
The method of claim 9, wherein said activin and said BMP are administered sequentially.
Claim 18
Dependent Claim 17 words
The method of claim 9, which further comprises administering an effective amount of TGF-β to the subject.
Claim 19
Dependent Claim 18 words
The method of claim 1, which further comprises administering an effective amount of bone marrow to the subject.
Claim 20
Dependent Claim 21 words
The method of claim 18 wherein said activin and said bone marrow are administered once per day for about 1-14 days.
Claim 21
Dependent Claim 10 words
The method of claim 18 wherein said subject has osteoporosis.
Claim 22
Dependent Claim 17 words
The method of claim 18, which further comprises administering an effective amount of TGF-β to the subject.
Claim 23
Dependent Claim 29 words
The method of claim 18, wherein said activin and said bone marrow are present in a ratio of about 0.001 μg:1 g to about 100 mg:1 g by weight.
Claim 24
Dependent Claim 22 words
The method of claim 18, wherein said bone marrow and said activin are administered in a composition comprising collagen and calcium phosphate.
Claim 25
Dependent Claim 15 words
The method of claim 18, wherein said activin and said bone marrow are administered simultaneously.
Claim 26
Dependent Claim 15 words
The method of claim 18, wherein said activin and said bone marrow are administered sequentially.
Claim 27
Dependent Claim 17 words
The method of claim 3 wherein the activin is administered once per day for about 3-10 days.
Claim 28
Dependent Claim 17 words
The method of claim 26 wherein the activin is administered once per day for about 7 days.
Claim 29
Dependent Claim 20 words
The method of claim 13 wherein said activin and said BMP are administered once per day for about 3-10 days.
Claim 30
Dependent Claim 20 words
The method of claim 28 wherein said activin and said BMP are administered once per day for about 7 days.
Claim 31
Dependent Claim 21 words
The method of claim 19, wherein said activin and said bone marrow are administered once per day for about 3-10 days.
Claim 32
Dependent Claim 21 words
The method of claim 30, wherein said activin and said bone marrow are administered once per day for about 7 days.

References Cited (Backward Citations)

US5071834A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1996-05-03 1996-11-02 1997-05-04 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2000-05-03 2000-11-02 2001-05-04 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2004-05-03 2004-11-02 2005-05-04 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag